deltatrials
Recruiting PHASE1 INTERVENTIONAL 4-arm NCT05519449

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Janux Therapeutics

Conditions Castration Resistant Prostatic Cancer Metastatic Castration-resistant Prostate Cancer Prostate Cancer
Interventions Darolutamide JANX007
Updated 19 times since 2022 Last updated: Jan 15, 2026 Started: Sep 15, 2022 Primary completion: Jul 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Castration Resistant Prostatic Cancer and Metastatic Castration-resistant Prostate Cancer, this trial is actively recruiting participants. The trial is conducted by Janux Therapeutics and has accumulated 19 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE1

  4. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  2. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE1

  3. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE1

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  6. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  7. Jan 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  8. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  10. Jun 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  12. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE1

  13. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

  14. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janux Therapeutics
Data source: Janux Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bedford Park, Australia , Birmingham, United States , Boston, United States , Camperdown, Australia , Charleston, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Hershey, United States and 22 more locations